Display options
Cite
Gadelha MR, Wildemberg LE, Kasuki L. The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab. 2021;doi: 10.1210/clinem/dgab726.
Gadelha, M. R., Wildemberg, L. E., & Kasuki, L. (2021). The future of somatostatin receptor ligands in acromegaly. The Journal of clinical endocrinology and metabolism, . https://doi.org/10.1210/clinem/dgab726
Gadelha, Monica R, et al. "The future of somatostatin receptor ligands in acromegaly." The Journal of clinical endocrinology and metabolism vol. (2021). doi: https://doi.org/10.1210/clinem/dgab726
Gadelha MR, Wildemberg LE, Kasuki L. The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab. 2021 Oct 07; doi: 10.1210/clinem/dgab726. Epub 2021 Oct 07. PMID: 34618894.
Copy Download .nbib Format: NLM
Share it on

J Clin Endocrinol Metab. 2021 Oct 07; doi: 10.1210/clinem/dgab726. Epub 2021 Oct 07.

The future of somatostatin receptor ligands in acromegaly.

The Journal of clinical endocrinology and metabolism

Monica R Gadelha, Luiz Eduardo Wildemberg, Leandro Kasuki

Affiliations

  1. Endocrine Unit and Neuroendocrinology Research Center, Medical School and Hospital Universitário Clementino Fraga Filho - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  2. Neuroendocrine Unit - Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro, Brazil.
  3. Neuropathology and Molecular Genetics Laboratory, Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro, Brazil.

PMID: 34618894 DOI: 10.1210/clinem/dgab726

Abstract

Currently, first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical control in approximately 40% of patients and tumor shrinkage in over 60% of patients. Pasireotide, a second-generation SRL, shows higher efficacy with respect to both biochemical control and tumor shrinkage but has a worse safety profile. In this review, we discuss the future perspectives of currently available SRLs, focusing on the use of biomarkers of response and precision medicine, new formulations of these SRLs and new drugs, which are under development. Precision medicine, which is based on biomarkers of response to treatment, will help guide the decision-making process by allowing physicians to choose the appropriate drug for each patient and improving response rates. New formulations of available SRLs, such as oral, subcutaneous depot and nasal octreotide, may improve patients' adherence to treatment and quality of life since there will be more options available that better suit each patient. Finally, new drugs, such as paltusotine, somatropin, ONO-5788 and ONO-ST-468, may improve treatment adherence and present higher efficacy than currently available drugs.

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.

Keywords: acromegaly; biomarker; precision medicine; somatostatin receptor; somatostatin receptor ligands

Publication Types